Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer

Minghai Shao, Stacy Hollar, Daphne Chambliss, Jordan Schmitt, Robert Emerson, Bhadrani Chelladurai, Susan Perkins, Mircea Ivan, Daniela Matei

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Antiangiogenic therapy is emerging as a highly promising strategy for the treatment of ovarian cancer, but the clinical benefits are usually transitory. The purpose of this study was to identify and target alternative angiogenic pathways that are upregulated in ovarian xenografts during treatment with bevacizumab. For this, angiogenesis-focused gene expression arrays were used to measure gene expression levels in SKOV3 and A2780 serous ovarian xenografts treated with bevacizumab or control. Reverse transcription-PCR was used for results validation. The insulin growth factor 1 (IGF-1) was found upregulated in tumor and stromal cells in the two ovarian xenograft models treated with bevacizumab. Cixutumumab was used to block IGF-1 signaling in vivo. Dual anti-VEGF and IGF blockade with bevacizumab and cixutumumab resulted in increased inhibition of tumor growth. Immunohistochemistry measured multivessel density, Akt activation, and cell proliferation, whereas terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay measured apoptosis in ovarian cancer xenografts. Bevacizumab and cixutumumab combination increased tumor cell apoptosis in vivo compared with therapy targeting either individual pathway. The combination blocked angiogenesis and cell proliferation but not more significantly than each antibody alone. In summary, IGF-1 activation represents an important mechanism of adaptive escape during anti-VEGF therapy in ovarian cancer. This study provides the rationale for designing bevacizumab-based combination regimens to enhance antitumor activity.

Original languageEnglish
Pages (from-to)1576-1586
Number of pages11
JournalMolecular Cancer Therapeutics
Volume11
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Ovarian Neoplasms
Vascular Endothelial Growth Factor A
Intercellular Signaling Peptides and Proteins
Insulin
Heterografts
Cell Proliferation
Apoptosis
Therapeutics
Gene Expression
Neoplasms
DNA Nucleotidylexotransferase
Stromal Cells
Reverse Transcription
Bevacizumab
Immunohistochemistry
Polymerase Chain Reaction
Antibodies
Growth
anti-IGF-1R antibody A12

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. / Shao, Minghai; Hollar, Stacy; Chambliss, Daphne; Schmitt, Jordan; Emerson, Robert; Chelladurai, Bhadrani; Perkins, Susan; Ivan, Mircea; Matei, Daniela.

In: Molecular Cancer Therapeutics, Vol. 11, No. 7, 07.2012, p. 1576-1586.

Research output: Contribution to journalArticle

Shao, Minghai ; Hollar, Stacy ; Chambliss, Daphne ; Schmitt, Jordan ; Emerson, Robert ; Chelladurai, Bhadrani ; Perkins, Susan ; Ivan, Mircea ; Matei, Daniela. / Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. In: Molecular Cancer Therapeutics. 2012 ; Vol. 11, No. 7. pp. 1576-1586.
@article{f8d82bbc98b449ba8ca2bd5aac8a2b85,
title = "Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer",
abstract = "Antiangiogenic therapy is emerging as a highly promising strategy for the treatment of ovarian cancer, but the clinical benefits are usually transitory. The purpose of this study was to identify and target alternative angiogenic pathways that are upregulated in ovarian xenografts during treatment with bevacizumab. For this, angiogenesis-focused gene expression arrays were used to measure gene expression levels in SKOV3 and A2780 serous ovarian xenografts treated with bevacizumab or control. Reverse transcription-PCR was used for results validation. The insulin growth factor 1 (IGF-1) was found upregulated in tumor and stromal cells in the two ovarian xenograft models treated with bevacizumab. Cixutumumab was used to block IGF-1 signaling in vivo. Dual anti-VEGF and IGF blockade with bevacizumab and cixutumumab resulted in increased inhibition of tumor growth. Immunohistochemistry measured multivessel density, Akt activation, and cell proliferation, whereas terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay measured apoptosis in ovarian cancer xenografts. Bevacizumab and cixutumumab combination increased tumor cell apoptosis in vivo compared with therapy targeting either individual pathway. The combination blocked angiogenesis and cell proliferation but not more significantly than each antibody alone. In summary, IGF-1 activation represents an important mechanism of adaptive escape during anti-VEGF therapy in ovarian cancer. This study provides the rationale for designing bevacizumab-based combination regimens to enhance antitumor activity.",
author = "Minghai Shao and Stacy Hollar and Daphne Chambliss and Jordan Schmitt and Robert Emerson and Bhadrani Chelladurai and Susan Perkins and Mircea Ivan and Daniela Matei",
year = "2012",
month = "7",
doi = "10.1158/1535-7163.MCT-11-0961",
language = "English",
volume = "11",
pages = "1576--1586",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer

AU - Shao, Minghai

AU - Hollar, Stacy

AU - Chambliss, Daphne

AU - Schmitt, Jordan

AU - Emerson, Robert

AU - Chelladurai, Bhadrani

AU - Perkins, Susan

AU - Ivan, Mircea

AU - Matei, Daniela

PY - 2012/7

Y1 - 2012/7

N2 - Antiangiogenic therapy is emerging as a highly promising strategy for the treatment of ovarian cancer, but the clinical benefits are usually transitory. The purpose of this study was to identify and target alternative angiogenic pathways that are upregulated in ovarian xenografts during treatment with bevacizumab. For this, angiogenesis-focused gene expression arrays were used to measure gene expression levels in SKOV3 and A2780 serous ovarian xenografts treated with bevacizumab or control. Reverse transcription-PCR was used for results validation. The insulin growth factor 1 (IGF-1) was found upregulated in tumor and stromal cells in the two ovarian xenograft models treated with bevacizumab. Cixutumumab was used to block IGF-1 signaling in vivo. Dual anti-VEGF and IGF blockade with bevacizumab and cixutumumab resulted in increased inhibition of tumor growth. Immunohistochemistry measured multivessel density, Akt activation, and cell proliferation, whereas terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay measured apoptosis in ovarian cancer xenografts. Bevacizumab and cixutumumab combination increased tumor cell apoptosis in vivo compared with therapy targeting either individual pathway. The combination blocked angiogenesis and cell proliferation but not more significantly than each antibody alone. In summary, IGF-1 activation represents an important mechanism of adaptive escape during anti-VEGF therapy in ovarian cancer. This study provides the rationale for designing bevacizumab-based combination regimens to enhance antitumor activity.

AB - Antiangiogenic therapy is emerging as a highly promising strategy for the treatment of ovarian cancer, but the clinical benefits are usually transitory. The purpose of this study was to identify and target alternative angiogenic pathways that are upregulated in ovarian xenografts during treatment with bevacizumab. For this, angiogenesis-focused gene expression arrays were used to measure gene expression levels in SKOV3 and A2780 serous ovarian xenografts treated with bevacizumab or control. Reverse transcription-PCR was used for results validation. The insulin growth factor 1 (IGF-1) was found upregulated in tumor and stromal cells in the two ovarian xenograft models treated with bevacizumab. Cixutumumab was used to block IGF-1 signaling in vivo. Dual anti-VEGF and IGF blockade with bevacizumab and cixutumumab resulted in increased inhibition of tumor growth. Immunohistochemistry measured multivessel density, Akt activation, and cell proliferation, whereas terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay measured apoptosis in ovarian cancer xenografts. Bevacizumab and cixutumumab combination increased tumor cell apoptosis in vivo compared with therapy targeting either individual pathway. The combination blocked angiogenesis and cell proliferation but not more significantly than each antibody alone. In summary, IGF-1 activation represents an important mechanism of adaptive escape during anti-VEGF therapy in ovarian cancer. This study provides the rationale for designing bevacizumab-based combination regimens to enhance antitumor activity.

UR - http://www.scopus.com/inward/record.url?scp=84863801971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863801971&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-11-0961

DO - 10.1158/1535-7163.MCT-11-0961

M3 - Article

C2 - 22700681

AN - SCOPUS:84863801971

VL - 11

SP - 1576

EP - 1586

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 7

ER -